if BG12 gets approved (think it will and soon) and they price it competitively, it will have taken a big bite out of the MS market by 2015.
Citi analyst John Boris thinks like you: "On the challenge from BG-12, Boris notes, At Citi’s Annual Cleveland Clinic meeting, a leading MS doctor noted high BG-12 demand, with their center warehousing patients ahead of approval… BG-12’s safety/efficacy pose a threat to ABCR therapies, including Copaxone. We project U.S. Copaxone sales of $2.90 billion 2012E declining to $1.26 billion in 2015."
Market Data 
Markets 
AI
